ABBV

SEC source: 0001179110-19-002369 · edgar.xml · nonDerivative · entry 3

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,787

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002369 · edgar.xml · nonDerivative · entry 2

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,447

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002369 · edgar.xml · nonDerivative · entry 1

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,097

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002370 · edgar.xml · derivative · entry 5

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,485

Underlying: Common Stock · 64,485 shares

Expires 2029-02-20

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,495 on February 21, 2020, 21,495 on February 21, 2021, and 21,495 on February 21, 2022.

SEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 4

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,567

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 3

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,002

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 2

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,013

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 1

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,638

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002371 · edgar.xml · derivative · entry 6

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,747

Underlying: Common Stock · 60,747 shares

Expires 2029-02-20

F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,249 on February 21, 2020, 20,249 on February 21, 2021, and 20,249 on February 21, 2022.

SEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 4

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,428

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 3

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,947

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 2

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,958

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 1

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,013

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002372 · edgar.xml · derivative · entry 5

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,535

Underlying: Common Stock · 68,535 shares

Expires 2029-02-20

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,845 on February 21, 2020, 22,845 on February 21, 2021, and 22,845 on February 21, 2022.

SEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 4

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,113

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 3

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,632

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,643

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002372 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,533

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002374 · edgar.xml · derivative · entry 9

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,127

Underlying: Common Stock · 179,127 shares

Expires 2029-02-20

F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 59,709 on February 21, 2020, 59,709 on February 21, 2021, and 59,709 on February 21, 2022.

SEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 4

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,812

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,207

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,098

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,449

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.

SEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 5

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 447,848

SEC source: 0001179110-19-000444 · edgar.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,565

F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 1,855 on 01/02/2020, 1,855 on 01/02/2021, and 1,855 on 01/02/2022, and include the right to have stock withheld for tax purposes.

SEC source: 0001179110-19-000231 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,222

Underlying: Common Stock · 74 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-19-000232 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,296

Underlying: Common Stock · 368 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-19-000235 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,768

Underlying: Common Stock · 352 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-19-000048 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,322

SEC source: 0001179110-18-014289 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,322

SEC source: 0001179110-18-014289 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,441

SEC source: 0001179110-18-013894 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,936

SEC source: 0001179110-18-013894 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,788

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2, above, upon certification by the Compensation Committee of AbbVie's Board of Directors of the achievement of specified strategic milestones.

SEC source: 0001179110-18-013893 · edgar.xml · nonDerivative · entry 1

CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,863

SEC source: 0001179110-18-013835 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,203

SEC source: 0001179110-18-013777 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,073

F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 21,514 on 12/09/2016, 21,513 on 12/09/2017, and 21,513 on 12/09/2018, and include the right to have stock withheld for tax purposes.

SEC source: 0001179110-18-013808 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,073

F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 3,865 shares on each of 12/10/2019, 12/10/2020 and 12/10/2021, and include the right to have stock withheld for tax purposes.

SEC source: 0001179110-18-013700 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,904

SEC source: 0001179110-18-013566 · edgar.xml · derivative · entry 6

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 94,140 shares

Expires 2024-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 5

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,258

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.515 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 4

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,558

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.98 to $92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 3

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,558

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,200

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013566 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-013330 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,053

SEC source: 0001179110-18-013337 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,350

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.24, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013331 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,258

SEC source: 0001179110-18-011829 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,190

Underlying: Common Stock · 343 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-18-011830 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,780

Underlying: Common Stock · 359 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-18-011832 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,082

Underlying: Common Stock · 72 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.